260 related articles for article (PubMed ID: 26351778)
1. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
[TBL] [Abstract][Full Text] [Related]
2. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
3. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.
Xiao Z; Chung H; Banan B; Manning PT; Ott KC; Lin S; Capoccia BJ; Subramanian V; Hiebsch RR; Upadhya GA; Mohanakumar T; Frazier WA; Lin Y; Chapman WC
Cancer Lett; 2015 May; 360(2):302-9. PubMed ID: 25721088
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
5. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.
Lee TK; Cheung VC; Lu P; Lau EY; Ma S; Tang KH; Tong M; Lo J; Ng IO
Hepatology; 2014 Jul; 60(1):179-91. PubMed ID: 24523067
[TBL] [Abstract][Full Text] [Related]
7. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
8. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
Yang HD; Kim HS; Kim SY; Na MJ; Yang G; Eun JW; Wang HJ; Cheong JY; Park WS; Nam SW
Hepatology; 2019 Oct; 70(4):1262-1279. PubMed ID: 30991448
[TBL] [Abstract][Full Text] [Related]
13. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
14. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents.
Wong NC; Cheung PF; Yip CW; Chan KF; Ng IO; Fan ST; Cheung ST
Mol Cancer Ther; 2014 Dec; 13(12):3001-12. PubMed ID: 25253787
[TBL] [Abstract][Full Text] [Related]
15. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
[TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD47 antibody synergizes with cisplatin against laryngeal cancer by enhancing phagocytic ability of macrophages.
Wang J; Zhang H; Yin X; Bian Y
Clin Exp Immunol; 2021 Sep; 205(3):333-342. PubMed ID: 33999416
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
[TBL] [Abstract][Full Text] [Related]
19. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
20. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma.
Tsang CM; Cheung KC; Cheung YC; Man K; Lui VW; Tsao SW; Feng Y
Biochim Biophys Acta; 2015 Mar; 1852(3):541-51. PubMed ID: 25496992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]